Want to see NL:PHARM full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
<0.01Last Year’s EPS
<0.01Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call balanced short-term headwinds (an expected RUCONEST revenue decline driven by inventory normalization, ex-U.S. exits and early competitive impacts; a near-term Q2 revenue risk; and some cash/one-time lease impacts) with several substantial positives: strong 34% YoY growth in Joenja, continued patient and prescriber additions for RUCONEST, successful regulatory progress (pediatric resubmission, CHMP positive opinion), upcoming Phase II readouts and napazimone enrollment completion, positive operating cash flow, and continued cost discipline. Management reaffirmed full-year guidance and emphasized pipeline catalysts and durable cash generation, indicating confidence in a return to growth in H2 2026 and beyond.Company Guidance
Total Q1 Revenue and Guidance Reaffirmed
Q1 2026 revenue of $72.4M (down 8% YoY) with full-year 2026 revenue guidance reaffirmed at $405M–$425M, implying ~8%–13% growth vs. 2025.
Strong Joenja Growth
Joenja revenue grew 34% YoY to $14.1M globally. U.S. paid patients reached 127 (up 25% YoY), net adds accelerated to 7 patients in the quarter and U.S. fill rate remained high at 85%.
RUCONEST Franchise Durability and New Prescribers
RUCONEST added ~50 new patient enrollments and 23 new prescribers in Q1, and management reports the overwhelming majority of RUCONEST patients have remained on therapy nine months after a new oral competitor launch.
Regulatory and Geographic Progress for Joenja
Meaningful regulatory progress: resubmission of pediatric sNDA (40 mg & 50 mg) in April with FDA decision expected in ~6 months; CHMP positive opinion obtained and Germany launch planned this year; Japan launch anticipated in August.
Pipeline Catalysts and Clinical Momentum
Two Phase II readouts for leniolisib in higher-prevalence PIDs are expected later this year; napazimone registrational study enrollment expected to complete in 2026 with readout in 2027; expanded access CVID data (n=6) show consistent clinical improvement and biomarker modulation.
Positive Operating Cash Flow and Strong Cost Discipline
Positive operating cash flow of $2.0M in Q1; total operating expenses down 9% YoY (flat after adjusting for one-time 2025 acquisition costs); company expects operating expenses $330M–$335M for 2026 and cites $9M benefit from prior 20% G&A headcount reduction.
Healthy Balance Sheet to Support Pipeline
Total cash and marketable securities of $171.8M at quarter-end and management expects available cash plus future operating cash flows to fully support planned pipeline and prelaunch activities.
NL:PHARM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NL:PHARM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | €1.40 | €1.03 | -25.81% |
Mar 12, 2026 | €1.37 | €1.33 | -3.42% |
Nov 06, 2025 | €1.10 | €1.37 | +24.25% |
Jul 31, 2025 | €0.85 | €0.97 | +14.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pharming Group (NL:PHARM) report earnings?
Pharming Group (NL:PHARM) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).
What is Pharming Group (NL:PHARM) earnings time?
Pharming Group (NL:PHARM) earnings time is at Jul 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Pharming Group stock?
The P/E ratio of Pharming Group is N/A.
What is NL:PHARM EPS forecast?
NL:PHARM EPS forecast for the fiscal quarter 2026 (Q2) is <0.01.